A PHASE 1/2, OPEN-LABEL, MULTICENTER STUDY OF THE COMBINATION OF NKTR-214 AND NIVOLUMAB OR THE COMBINATION OF NKTR-214, NIVOLUMAB, AND OTHER ANTI-CANCER THERAPIES IN PATIENTS WITH SELECT LOCALLY ADVANCED OR METASTATIC SOLID TUMOR MALIGNANCIES
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Nektar Therapeutics
Start Date
July 15, 2019
End Date
October 20, 2020
Administered By
Duke Cancer Institute
Awarded By
Nektar Therapeutics
Start Date
July 15, 2019
End Date
October 20, 2020